Docoh
Loading...

NEO Neogenomics

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Company profile

Ticker
NEO
Exchange
CEO
Douglas M. Van Oort
Employees
Incorporated
Location
Fiscal year end
Former names
AMERICAN COMMUNICATIONS ENTERPRISES INC
SEC CIK
Subsidiaries
NeoGenomics Laboratories, Inc. • NeoGenomics Bioinformatics, Inc. • NeoGenomics Foundation, Inc. • Genesis Acquisition Holdings Corp. • Genoptix, Inc. • Minuet Diagnostics, Inc. • Cynogen, Inc. • Clarient, Inc. • Clarient Diagnostic Services, Inc. • NeoGenomics Europe, SA ...
IRS number
742897368

NEO stock data

(
)

Calendar

9 Aug 21
16 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Neogenomics earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 372.9M 372.9M 372.9M 372.9M 372.9M 372.9M
Cash burn (monthly) 83.4M (positive/no burn) (positive/no burn) (positive/no burn) 463.33K (positive/no burn)
Cash used (since last report) 295.74M n/a n/a n/a 1.64M n/a
Cash remaining 77.16M n/a n/a n/a 371.26M n/a
Runway (months of cash) 0.9 n/a n/a n/a 801.3 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
11 Oct 21 Tetrault LYNN A. Common Stock Grant Acquire A No No 0 838 0 35,777
11 Oct 21 Tetrault LYNN A. Stock Option Common Stock Grant Acquire A No No 41.76 972 40.59K 972
17 Aug 21 Gilbert Halley E Common Stock Grant Acquire A No No 0 59,228 0 59,228
17 Aug 21 Gilbert Halley E Common Stock Common Stock Grant Acquire A No No 42.21 63,331 2.67M 63,331
1 Aug 21 Oort Douglas M Van Common Stock Payment of exercise Dispose F No No 46.1 5,919 272.87K 2,468,797

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

89.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 305 329 -7.3%
Opened positions 32 45 -28.9%
Closed positions 56 50 +12.0%
Increased positions 104 114 -8.8%
Reduced positions 102 117 -12.8%
13F shares
Current Prev Q Change
Total value 5.4B 5.16B +4.6%
Total shares 110.24M 106.8M +3.2%
Total puts 130K 128.3K +1.3%
Total calls 176.1K 588K -70.1%
Total put/call ratio 0.7 0.2 +238.3%
Largest owners
Shares Value Change
BLK Blackrock 18.72M $845.7M -0.1%
Vanguard 12.2M $550.96M +1.4%
Wellington Management 5.55M $250.61M +27.4%
Artisan Partners Limited Partnership 4.84M $218.82M -0.2%
IVZ Invesco 4.49M $202.99M -6.8%
JHG Janus Henderson 4.43M $199.98M +7.9%
STT State Street 3.49M $157.62M +5.8%
Brown Advisory 3.31M $149.53M +5.3%
AMP Ameriprise Financial 2.48M $112.13M +34.8%
Fred Alger Management 2.03M $91.52M -9.7%
Largest transactions
Shares Bought/sold Change
Avidity Partners Management 1.37M +1.37M NEW
Wellington Management 5.55M +1.19M +27.4%
WDR Waddell & Reed Financial 0 -897.05K EXIT
MCQEF Macquarie 871.71K +867.88K +22636.3%
Mirae Asset Global Investments 0 -716.55K EXIT
Blue Water Life Science Advisors 702.22K +702.22K NEW
AMP Ameriprise Financial 2.48M +641.44K +34.8%
Casdin Capital 488.89K +488.89K NEW
Farallon Capital Management 420K +420K NEW
Compagnie Lombard Odier SCmA 0 -361.01K EXIT

Financial report summary

?
Risks
  • We may be unable to make, on a timely basis, necessary changes to our internal control structure resulting from the acquisitions of Trapelo and Inivata.
  • Trapelo and Inivata may have liabilities that are not known, probable or estimable at this time.
Management Discussion
  • •We acquired the Oncology Division assets of Human Longevity, Inc. (“HLI - Oncology”);
  • •High-capacity COVID-19 testing lab operationalized.
  • Advances in science and technology are driving a proliferation of oncology therapies and associated diagnostic tests. These diagnostic tools and therapies are increasing survival and enhancing quality-of-life for cancer patients. As a leading global oncology diagnostics company serving biopharmaceutical companies as well as practicing oncologists and pathologists, NeoGenomics facilitates the adoption of these advanced oncology diagnostic tools beyond the academic environment into the community setting. We are continuously enhancing and expanding our test menu to ensure that providers and patients have access to leading edge solutions such as advanced molecular testing and state-of-the art digital pathology. Moreover, our team of MDs and PhDs, along with our highly-trained oncology-focused sales team provide continuous education to our clients to ensure that they remain abreast of cutting-edge developments in oncology.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: accredited, administered, alleged, alleging, answer, assembled, avoided, behalf, British, Cambridge, Cardoza, Carolina, Certification, Clive, compensatory, complaint, compliance, confidence, Court, defend, Delaware, diligence, Director, district, duly, earliest, enterprise, ERP, exhibit, external, failed, forma, formatted, George, Gina, good, guarantee, harm, illustrative, indemnification, Inline, investor, IRS, ix, iXBRL, Kathryn, Kingdom, knowledgeable, Language, learn, Mallon, Mark, match, matching, McKenzie, migrating, NaNne, Natera, Oracle, ordinary, outcome, page, Park, patent, pending, pension, pro, redacted, representation, reputation, resource, return, royalty, shifted, tangible, thereunto, Title, trademark, Triangle, turn, unasserted, undersigned, vigorously, voluntary, Wallar, warranty
Removed: consistency, Joint, largely, lower, Simplifying, succeeding